Doubling up over heparin
Regado's data for reversible anticoagulant to avoid bleeding, ischemic events
Regado Biosciences Inc. thinks its two-part reversible anticoagulants - consisting of a therapeutic aptamer and a complementary inhibitory aptamer - can improve outcomes vs. heparin for acute coronary syndrome in the acute care setting. The company said Phase IIb data show its lead aptamer pair can avoid the bleeding or ischemic events that result from too much or too little anticoagulation.
Regado plans to move into Phase III testing next year in acute coronary syndrome (ACS) patients undergoing open heart surgery.
The lead program, REG1, consists of a therapeutic aptamer called pegnivacogin (RB006) and a control agent called anivamersin (RB007). The control aptamer has no pharmacologic activity other than to bind to and deactivate the therapeutic aptamer, so the